No Data
No Data
Earnings Preview: Arvinas to Report Financial Results on May 01
Arvinas Reports Preclinical Results for New Lymphoma Drug Combo at Cancer Research Meeting
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Arvinas Announces Late-Breaking Oral Presentation of Phase 3 VERITAC-2 Trial Results for Vepdegestrant at ASCO 2025
Express News | Arvinas Announces Results From the Veritac-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (Asco) Annual Meeting
Arvinas Announces Results From the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
FindaCure : Very exciting results in mice, but let's see how this is translated into human.